[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombolysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombolysis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,74,103,128,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636283","phase-4-early-low-dose-aspirin-use-after-intravenous-thrombolysis-for-acute-ischemic-cerebral-infarctionelastic-100636283",false,"NCT07563673","Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）","Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial","ELASTIC","Inclusion Criteria:\n\n1. Age range: 18-65 years old\n2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset\n3. Signs of brain dysfunction lasting for more than 1 hour\n4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs\n\nExclusion Criteria:\n\n1. Age\\>65 years old\n2. Onset time\\>3 hours\n3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points\n4. CT shows' high-density shadow of middle cerebral artery '\n5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism\n6. Severe swallowing difficulties, unable to take medication orally\n7. Oral anticoagulant medication is currently being taken\n8. Accompanied by severe infection or evidence of severe infection\n9. Refusal to sign the informed consent form for this study\n10. Exclusion criteria for other traditional intravenous thrombolysis","ALL","18 Years","65 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.",[28,29],"Cerebral Infarction","Thrombolysis","NOT_YET_RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":22},"2026-05-01",{"date":38,"type":22},"2027-12-31",{"name":40,"class":41},"Beijing Chao Yang Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100614412","phase-2-thrombolysis-in-early-acute-ischemic-stroke-trial-blood-pressure-management-100614412","NCT07279259","Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management","Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP","EAST-BP","Inclusion Criteria:\n\n1. Age 18 to 80 years (inclusive);\n2. Patients with acute ischemic stroke;\n3. Planned to receive intravenous thrombolysis within 4.5 hours of onset;\n4. Elevated blood pressure: Before receiving intravenous thrombolysis treatment, blood pressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes);\n5. Informed consent signed (or signed by a proxy).\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma).\n2. History of intracranial hemorrhage; severe head trauma or stroke within the last 3 months.\n3. Intracranial tumors, giant intracranial aneurysms.\n4. Intracranial or spinal surgery within the last 3 months; major surgery within the last 2 weeks; arterial puncture at a site not easily compressed for hemostasis within the last 7 days.\n5. Gastrointestinal or urinary system bleeding within the last 3 weeks.\n6. Aortic dissection.\n7. Acute bleeding tendency, including platelet count \\\u003C 100×10\\^9\u002FL or other bleeding tendencies.\n8. Received low-molecular-weight heparin orally within 24 hours; taking warfarin with INR \\> 1.7 or PT \\> 15 seconds; used a new oral anticoagulant within 48 hours.\n9. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n10. Large area cerebral infarction indicated on head CT or MRI (infarction area \\> 1\u002F3 of the middle cerebral artery territory).\n11. Active visceral hemorrhage, known bleeding diathesis or significant bleeding disorders within the past 6 months\n12. Severe ischemic stroke (NIHSS score \\> 25)\n13. Epileptic seizures at the time of stroke onset\n14. Pregnant or lactating women\n15. Various terminal diseases with an expected survival of ≤ 3 months\n16. Any other physical conditions where the doctor deems participation in this study may be detrimental to the patient\n17. Currently participating in other drug or device clinical trials\n18. mRS score \\> 2 before onset of the disease.","80 Years",{"count":53,"type":22},340,[55],"PHASE2","This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).",[58,59,29],"Stroke","Acute Ischemic Stroke",[61,62,63],"acute ischemic stroke","blood pressure","thrombolysis","RECRUITING","2026-01-18",{"date":67,"type":34},"2026-01-21",{"date":69,"type":22},"2026-01-15",{"date":71,"type":22},"2028-08-05",{"name":73,"class":41},"Shanghai East Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006","NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.",{"count":82,"type":22},462,"OBSERVATIONAL","Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[58,29,86,87,59],"DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)",[89,90,29,91,92],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","2025-12-10",{"date":95,"type":34},"2025-12-23",{"date":97,"type":22},"2026-01-01",{"date":99,"type":22},"2026-04-30",{"name":101,"class":41},"Sigmund Freud PrivatUniversitat",7,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100605880","phase-3-tenecteplase-vs-medical-management-in-45-24h-lvo-no-access-to-evt-100605880","NCT07168278","Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","Tenecteplase vs Medical Management in 4.5-24h Anterior Circulation Large Vessel Occlusion With no Access to EVT","TNK LATE","Inclusion Criteria:\n\n* Age 18 years or greater\n* Acute ischemic stroke presenting in the 4.5 to 24 hour window from last seen well (including wake-up stroke and no witness stroke).\n* Prestroke mRS 0-2\n* NIHSS 6 to 25\n* Aspect ≥ 7\n* ICA terminus, M1, dominant M2 occlusion on CTA or MRA\n* Clinical-imaging mismatch assessed by investigator\n* Patients with no access to EVT at the time of randomization\n\nExclusion Criteria:\n\n* Current or past history of significant bleeding over the past 6 months;\n* History of intracranial hemorrhage (including possible subarachnoid hemorrhage or subarachnoid hemorrhage due to an aneurysm) or evidence or suspected intracranial hemorrhage;\n* Known bleeding tendency;\n* Recent severe or dangerous bleeding, or active ulcerative gastrointestinal disease;\n* History of central nervous system injury (e.g., intracranial tumor, aneurysm, or arteriovenous malformation, intracranial or spinal surgery), or recent head injury；\n* Tumors that increase risk of bleeding;\n* Severe liver dysfunction, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis;\n* Know arterial \u002F venous malformation or aneurysm;\n* Bacterial endocarditis, pericarditis, or acute pancreatitis;\n* Patients receiving effective anticoagulant therapy (vitamin K antagonists with INR \\> 1.3, or other oral anticoagulants exceeding the upper limit of the corresponding standard range);\n* Heparin use within the past 48 hours and prothrombin time exceeding the upper limit of the standard range;\n* Over the past 3 months, undergone major surgery, organ biopsy, or suffered a serious injury;\n* Over the past 2 weeks, receiving prolonged ( \\>2 minutes) cardiopulmonary resuscitation, childbirth, or non-stressful vascular puncture (such as subclavian or jugular vein puncture);\n* Stroke episode occurred with epileptic seizure;\n* History of stroke comorbid with diabetes;\n* History of stroke over the past 3 months；\n* Acute bleeding tendency, including platelet count below 100×10⁹\u002FL or other conditions;\n* SBP \\>185 mmHg or DBP \\>110 mmHg, or requiring intensive treatment (intravenous antihypertensive drugs) to lower blood pressure to within limits;\n* Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL (\\\u003C50 mg\u002FdL or \\>400 mg\u002FdL)；\n* Patient life expectancy of less than 1 year;\n* Simultaneous occlusion of multiple blood vessels, defined as bilateral MCAs or MCAs combined with the basilar artery;\n* Pregnant women or nursing mothers；\n* Patients with a low likelihood of 3-month follow-up；\n* Over the past 3 months participated in other interventional clinical trials.",{"count":112,"type":22},794,[114],"PHASE3","The goal of this clinical trial is to learn if tenectplase works to acute ischemic stroke (AIS) with onset 4.5-9 hours. It will also learn about the safety of tenectplase in AIS with onset 4.5-9 hours. The main question it aims to answer is: Does tenectplase improve the 90-days functional outcome in participants with acute large vessel occlusion? Researchers will compare tenectplase thrombolysis to non-use to see if tenectplase works to improve the functional outcome in participants with onset 4.5-9 hours. Participants will:\\* Receive 0.25mg\u002Fkg (max 25mg) tenectplase at admission (after randomization) .\\* Receive neurological assessment at admission, Day 5-7 or on hospital discharge (whichever earlier). Audio or video of the assessment may be recorded if possible.\\* Receive brain CT + CT angiogram + CT perfusion and MRI after randomization, where the CT scan may be repetitive.",[59,117,118,29],"Large Vessel Occlusion","Tenecteplase","2025-09-05",{"date":121,"type":34},"2025-09-11",{"date":123,"type":22},"2025-11-01",{"date":125,"type":22},"2028-05-31",{"name":127,"class":41},"The First Affiliated Hospital of University of Science and Technology of China",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":102},"100571957","rescue-stenting-and-intravenous-thrombolysis-in-patients-with-large-vessel-ischemic-stroke-100571957","NCT06727006","Rescue Stenting and Intravenous Thrombolysis In Patients With Large Vessel Ischemic Stroke","Stroke, Thrombolysis and Rescue Stenting","STARS","Inclusion Criteria:\n\n* Patients with large vessel occlusion strokes undergoing thrombectomy and rescue stenting within 24 hours of stroke onset\n* Patients ≥ 18 years of age\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Refusal to give informed consent",{"count":137,"type":22},400,"Intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for treating selected patients with acute large-vessel occlusion stroke (LVOS). Successful revascularization is strongly correlated with favorable outcomes. Nevertheless, recanalization failure with stent retrieval and contact aspiration has been observed in up to 29% of patients. If primary thrombectomy fails to achieve recanalization, rescue stenting (RS) has proven to be a feasible rescue therapy. Currently, approved evidence-based alternatives for LVOS patients who have failed MT are lacking, but permanent stenting is suggested as a rescue treatment in expert consensus statements.\n\nDual antiplatelet therapy (DAPT), typically consisting of clopidogrel and aspirin, is recommended after stent implantation to reduce the risk of stent thrombosis; however, these medications are not suitable in the acute setting, and optimal platelet inhibition strategies remain unclear. Glycoprotein (GP) IIb\u002FIIIa receptor inhibitors have intravenous administration, a rapid onset of action, and their effects subside within a few hours after discontinuation. For these reasons, an increasing number of studies have investigated their use in conjunction with primary stenting for acute stroke. Currently, there is no evidence supporting the superiority of any particular antithrombotic strategy, so decisions are guided by clinical judgment.\n\nAn additional challenge for clinicians arises when IVT is combined with stenting. Stroke guidelines recommend starting antiplatelets 24 hours after IVT and the risk associated with antithrombotic therapy within the first 24 hours after IVT remains uncertain.\n\nThis is multicenter, prospective, observational study of patients with LVOS undergoing mechanical thrombectomy and rescue stenting. The aim of this study is to evaluate real-world antithrombotic strategies in emergency stenting, particularly in patients treated with IVT, and to assess the safety of emergent stenting following intravenous thrombolysis.",[117,140,29,141],"Stroke Acute","Rescue Stenting",[143,29],"Rescue stenting","2024-12-14",{"date":146,"type":34},"2024-12-17",{"date":148,"type":34},"2023-10-21",{"date":150,"type":22},"2027-03",{"name":152,"class":41},"ASST Santi Paolo e Carlo",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":163,"studyType":83,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100471907","application-of-standardized-green-channel-treatment-system-for-ischemic-stroke-in-xi-an-100471907","NCT05424978","Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an","Asgctsis","Inclusion Criteria:\n\n* 18 years old;\n* Consistent with the diagnosis of acute ischemic stroke;\n* 24 hours from onset to enrollment;\n* Informed consent\n\nExclusion Criteria:\n\n* Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);\n* Stroke patients caused by brain tumor, brain trauma and blood diseases;\n* Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;\n* Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;\n* Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);\n* Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;\n* Other diseases that limit neurological function evaluation or affect patient follow-up;\n* A woman planning to be pregnant or breastfeeding;\n* Currently participating in other clinical trials;\n* Refuse to participate in the registration of investigators","100 Years",{"count":162,"type":22},3600,"90 Days","Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.",[59,29,166],"Endovascular Treatment","2024-01-24",{"date":169,"type":34},"2024-01-26",{"date":171,"type":34},"2022-06-01",{"date":173,"type":22},"2028-07-31",{"name":175,"class":176},"Xi'an No.3 Hospital","OTHER_GOV"]